CD40 and myeloid sarcoma: When the RIS group was divided into individuals who developed MS symptoms during follow-up and those who did not, no significant differences were observed between the groups in CD40 and CD71 expression across the different B cell subsets (Figure 3; Supplementary Figure S4, respectively).